[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345880-105":59,"doc-detail-345880-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","urinary-and-cellular-volatile-organic-compounds-as-biomarkers-for-urological-cancers-a-systematic-review-of-gc-ms-based-volatolomics","Urinary and cellular volatile organic compounds as biomarkers for urological cancers - a systematic review of GC-MS-based volatolomics","","Volatile organic compounds in human biofluids are investigated as promising non-invasive biomarkers, yet their role in urological cancers and the consistency between urinary and cellular volatile organic compound profiles across prostate, bladder, and kidney cancers remains unclear. This systematic review evaluates GC-MS-based untargeted volatolomics evidence, extracts biomarker candidates and analytical factors, and compares diagnostic performance. Twelve urinary prostate, nine urinary bladder, five urinary renal, and three cellular studies are integrated to identify unique and cross-matrix volatile organic biomarkers and highlight methodological heterogeneity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/urinary-and-cellular-volatile-organic-compounds-as-biomarkers-for-urological-cancers-a-systematic-review-of-gc-ms-based-volatolomics/345880/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/urinary-and-cellular-volatile-organic-compounds-as-biomarkers-for-urological-cancers-a-systematic-review-of-gc-ms-based-volatolomics/345880.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of this systematic review?","Question",{"text":113,"@type":114},"To evaluate GC-MS-based untargeted volatolomics studies for urological cancers, identify cancer-specific and cross-cancer VOC biomarkers, compare urine versus cellular matrices, and assess methodological factors affecting biomarker discovery.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were VOC biomarkers across studies compared?",{"text":118,"@type":114},"The review extracted and compared VOC biomarker identities, direction of change, diagnostic performance, sampling methods, analytical platforms, compound identification strategies, and statistical approaches across prostate, bladder, and kidney cancers.",{"name":120,"@type":111,"acceptedAnswer":121},"What key findings were reported about VOC patterns and shared biomarkers?",{"text":122,"@type":114},"The review identified decreased organic acids and alcohols in prostate cancer, and more frequent elevations of ketones and aldehydes in bladder and renal cancers. It also reported cross-matrix shared VOCs, including aligned trends for several compounds, supporting both unique and recurrent metabolic alterations.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345880,1790167134,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Metabolomics (2026) 22:133  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1306-026-02493-7  \nREVIEW ARTICLE  \nUrinary and cellular volatile organic compounds as biomarkers forurological cancers: a systematic review of GC-MS-based volatolomics  \nBoyu Xie1,3 · QingWen2,3  \nReceived: 7 March 2026 / Accepted: 8 June 2026 / Published online: 27 July 2026 © The Author(s) 2026  \nAbstract  \nIntroduction Volatile organic compounds (VOCs) in human biofluids are promising non-invasive cancer biomarkers. However, their potential in urological cancers, including prostate, bladder, and kidney cancers is less explored, and the relationships between urinary and cellular VOC profiles across these cancer types remain unclear.  \nObjectives This systematic review aimed to evaluate gas chromatography-mass spectrometry (GC-MS)-based untargeted volatolomics studies in urological cancers to investigate cancer-specific, cross-cancer, and cross-matrix (urine vs. cell culture media) VOC biomarkers, while assessing methodological factors influencing biomarker discovery.  \nMethods Published urinary and cellular VOC studies in prostate, bladder, and kidney cancers were systematically reviewed. VOC biomarkers, direction of change, diagnostic performance, sampling methods, analytical platforms, compound-identification strategies, and statistical approaches were extracted and compared across cancer types and sample matrices.  \nResults A total of 12 urinary prostate, 9 urinary bladder, 5 urinary renal, and 3 cellular VOC studies were identified. Prostate cancer profiles were mainly characterized by decreased organic acids and alcohols, whereas bladder and renal cancers more frequently showed elevated ketones and aldehydes. Several VOCs, including 2-butanone, 2-heptanone, hexanal and phenol, were identified across multiple cancer types. Cellular studies showed consistent directional changes for six VOCs, and cross-matrix analysis identified 28 shared VOCs, seven of which showed aligned trends in urine and cell models. These findings suggest that VOCs reflect both unique and shared metabolic alterations in urological cancers and may serve as useful diagnostic biomarker candidates.  \nConclusion This review integrates urinary and cellular VOC data across major urological cancers and identifies unique, recurrent, and cross-matrix VOCs that warrant further mechanistic and clinical validation. Although methodological heterogeneity remains a challenge, VOC-based approaches have generally shown good sensitivity and specificity for distinguishing malignant from healthy controls. With improved and standardized analytical methods, VOC volatolomics may support the future development of non-invasive and accurate diagnostics for urological cancers.  \nKeywords Volatile organic compounds (VOCs) · Urological cancers · Gas chromatography-mass spectrometry (GC– MS) · Urinary biomarkers · Cellular volatolomics · Cancer diagnosis  \n1 Introduction  \n Boyu Xie [boyu.xie@imperial.ac.uk](boyu.xie@imperial.ac.uk)  \n1 Faculty of Biophysics, Biochemistry and Molecular Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China  \n2 Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China  \n3 Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK  \n1.1 Biological basis and history of volatile organic compound biomarker discovery  \nVolatile organic compounds (VOCs) are defined as compounds with high vapor pressure and a boiling point\u003C 250 °Cat 101.3 kPa (WHO, 1989). VOCs can be produced through various endogenous metabolic processes in human, such as lipid peroxidation, enzyme catabolism, and gut microbiota metabolism (Janfaza et al., 2019; Ruzsanyi et al., 2022) . Their profiles can also be altered by pathological conditions  \nsuch as inflammation, neoplasia, and tumorigenesis, and the disease-associated changes in VOC profiles are detectable in human biofluids, enabling their us","cbCaitkHiKgQbMMI","https://ap.wps.com/l/cbCaitkHiKgQbMMI","pdf",1390801,23,"English","# Abstract\n# Introduction\n## Biological basis and history of volatile organic compound biomarker discovery\n# Objectives\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What is the main goal of this systematic review?\",\"answer\":\"To evaluate GC-MS-based untargeted volatolomics studies for urological cancers, identify cancer-specific and cross-cancer VOC biomarkers, compare urine versus cellular matrices, and assess methodological factors affecting biomarker discovery.\"},{\"question\":\"How were VOC biomarkers across studies compared?\",\"answer\":\"The review extracted and compared VOC biomarker identities, direction of change, diagnostic performance, sampling methods, analytical platforms, compound identification strategies, and statistical approaches across prostate, bladder, and kidney cancers.\"},{\"question\":\"What key findings were reported about VOC patterns and shared biomarkers?\",\"answer\":\"The review identified decreased organic acids and alcohols in prostate cancer, and more frequent elevations of ketones and aldehydes in bladder and renal cancers. It also reported cross-matrix shared VOCs, including aligned trends for several compounds, supporting both unique and recurrent metabolic alterations.\"}]","Urinary and cellular volatile organic compounds as biomarkers for urological cancers - a systematic review of GC-MS-based volatolomics | PDF",1790059220,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84a9cd4cba71c698951cc5083c9e3966.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e4e011bf19160396559d70f0744101e.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/533cb1223cad9fbc21c7aec2c62ed0e5.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7bdd4d77d9dce8d1a69e8be40b42399e.webp",980,1301]